Home MarketStrides Shasun Ltd.

Strides Shasun Ltd. Stock Info: As on 2018-05-24 15:59:56

Nse

412.55

9.35(2.32%)
Change%
52 Week Range
333.30
21.00
1,102.20
24.00
Open412.00
Day's Range362.88 - 443.52
Value Traded (in ₹ Cr.) 301.77

Bse

412.20

7.30(1.80%)
Change %
52 Week Range
337.05
21.00
1,101.65
24.00
Open411.70
Day's Range364.41 - 445.39
Value Traded (in ₹ Cr.) 27.96

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 28,068,384.00 31.36%
Mutual Funds/UTI 16,658,405.00 18.61%
FII 28,175,817.00 31.48%
Employee 0.00 0.00%
Public 9,237,184.00 10.32%
Government 0.00 0.00%
Others 6,262,480.00 7.00%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.65
Basic EPS (Rs.) 12.15
Cash EPS 26.30
BVPerShare Excl 361.49
Operating Revenue 235.93
PBDITPerShare 51.21
Dividend 4.50
NPPerShare 12.14
Current Ratio 1.83
Quick Ratio 1.54
PriceToBV 3.03
Earnings 0.01
PBDIT Margin 21.70
PBT Margin 6.54
NP Margin 5.14
Return On Assets 1.98
Retention Ratios 67.06
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 2,285.94
Total Expenses 2,069.35
EBITDA 457.96
PBT 138.13
PAT 122.77
Net Income 108.54
More
Parameter Mar-18 (₹ Cr.) 6M % change
Total Income 794.67
Total Expenses 626.54
EBITDA 126.08
PBT 111.00
PAT 106.18
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 89.42
Net worth 3,232.53
Investments 2,598.72
Total Liability 5,481.24
Total debt 1,416.90
Net block 1,351.58
Total Assets 5,481.24
Parameter Mar-17 (₹ Cr.) 6M % change
Total share capital 89.35
Net worth 3,135.40
Investments 2,366.87
Total Liability 5,363.99
Total debt 1,425.11
Net block 1,238.92
Total Assets 5,363.99
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533.05 531.95 0.21
524.95580

Abbott India Ltd.

6671.7 6587.45 1.28
65106890

Ajanta Pharma Ltd.

977.6 987 -0.95
962.351074.5

Albert David Ltd.

362.35 362.75 -0.11
356.2383.15

Alembic Ltd.

48.85 50.8 -3.84
50.254

Alembic Pharmaceuticals Ltd.

420.7 422.3 -0.38
418.5491.2

Alkem Laboratories Ltd.

1957.55 1965.35 -0.4
18882036.65
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

47.5 49.05 -3.16
46.351.55

Aarti Drugs Ltd.

530 529.15 0.16
526585

Aayush Food & Herbs Ltd.

47.7 48.1 -0.83
4355

Abbott India Ltd.

6699.95 6593.7 1.61
6465.056872.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 411.74
Cash from investing activities -344.05
Cash from financing activities -67.24
Net change in cash -538.32

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
SBI Blue Chip Fund 0.86%
SBI Magnum Midcap Fund 2.36%
DSP BlackRock Equity & Bond Fund 1.04%
SBI Healthcare Opportunities Fund 7.71%
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.33%
DSP BlackRock Tax Saver Fund 1.27%

M Venkatesh appointed MRPL MD

M Venkatesh has been appointed as the Managing Director of Mangalore Refineries and Petrochemicals Limited (MRPL), an order issued by the Personnel Ministry said today. Vekatesh is at present Director (Refineries) in the MRPL, a subsidiary of the Oil and Natural Gas Corporation Limited (ONGC) He has been appointed to the post for a period of five years with effect from the date of his assumption of charge of the post on or after June 1, 2018, or till the date of his superannuation, the order said.

24-05-2018 11:42

TCS expands operations in Florida as part of Transamerica deal

India's largest IT services firm TCS today said it has expanded operations in Florida, US, with over 430 employees joining the company as part of its deal with Transamerica. In January, Tata Consultancy Services (TCS) had signed an over USD 2 billion deal with Transamerica to administer the latter's life insurance, annuity, supplemental health insurance, and workplace voluntary benefits products. It covered managing administration of more than 10 million policies. More than 430 former Transamerica employees now work for TCS at this new St Petersburg facility (in Florida) as part of recruiting and investing in more than 2,200 Transamerica jobs across the US in multiple locations, the Indian software services giant said in a statement. TCS will occupy several floors of Transamerica's building at 570 Carillon Parkway in St Petersburg, as part of a multi-year agreement with Transamerica... The St Petersburg office is a new US business centre for TCS, adding to the over 1,000 employees already serving American businesses throughout the state, it added. TCS said it has invested nearly USD 3 billion in the US over the past three years and has been among the top two IT services job creators in the country. TCS is a leading industry employer in the US, striving to help American companies like Transamerica to digitally transform their business and capitalise on rapidly evolving customer demands, TCS President and Global Head (Banking, Financial Services and Insurance Platforms) Suresh Muthuswami said. We look forward to partnering with St Petersburg's city, state and local organizations to further build upon our business and community impact, he added. The company said it has made tremendous community impact in Florida over past several years.

24-05-2018 11:16

Kotak India Growth Fund Series 4 - Direct Plan: change in investment factsheets for April

Kotak India Growth Fund Series 4 - Direct Plan has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.89 for Growth, while 52-Week High and Low ranges were Rs 10.35 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 - Direct Plan is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

Kotak India Growth Fund Series 4: change in investment factsheets for April

Kotak India Growth Fund Series 4 has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.88 for Growth, while 52-Week High and Low ranges were Rs 10.34 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

BLS International to assist Sopra Steria on UK visa renewals

Visa service provider BLS International today said theUnited Kingdom Visas and Immigration (UKVI) has awarded Sopra Steria a new contract to enable visa renewals for those individuals who are already in the UK. BLS International will support Sopra Steria and UKVI, a division of the UK Home Office responsible for deciding who can visit and stay within the UK, by establishing and delivering some of the key add value services under the contract, it said in a release. BLS International claims to handle about 12 million visa applications annually across the globe at present. Meanwhile, shares of the company were trading at Rs 172.55 apiece, up 1 per cent from the previous close at 10:50 hours on BSE.

24-05-2018 10:51

Strides Shasun L - Announcement under Regulation 30 (LODR)-Scheme of Arrangement

Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

18-May-2018 04:37 PM

Strides Shasun L - Board Meeting-Outcome of Board Meeting

Outcome of the Board Meeting - Board Reconstitution

18-May-2018 04:35 PM

Strides Shasun L - Outcome of Board Meeting

Strides Shasun Limited has informed the Exchange regarding the Scheme of Amalgamation for merger of its Wholly Owned Subsidiaries.

18-May-2018 04:26 PM

Strides Shasun L - Outcome of Board Meeting

Strides Shasun Limited has informed the Exchange regarding Board Reconstitution effective May 18, 2018

18-May-2018 04:22 PM

Strides Shasun L - Board recommends Final Dividend

Strides Shasun Ltd has informed BSE that the Board of Directors at their meeting held on May 18, 2018, inter alia, have recommended final dividend of 20% at Rs. 2/- per share for the year ended March 31, 2018. The dividend payout shall be made within 30 days from the date of shareholder approval at the ensuing Annual General Meeting of the Company.

18-May-2018 01:56 PM

Strides Shasun L - Announcement under Regulation 30 (LODR)-Scheme of Arrangement

Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

18-May-2018 04:37 PM

Strides Shasun L - Board Meeting-Outcome of Board Meeting

Outcome of the Board Meeting - Board Reconstitution

18-May-2018 04:35 PM

Strides Shasun L - Board recommends Final Dividend

Strides Shasun Ltd has informed BSE that the Board of Directors at their meeting held on May 18, 2018, inter alia, have recommended final dividend of 20% at Rs. 2/- per share for the year ended March 31, 2018. The dividend payout shall be made within 30 days from the date of shareholder approval at the ensuing Annual General Meeting of the Company.

18-May-2018 01:56 PM

Corporate Details

About Management

2002 -Board approves for the allotment of 210,955 shares of the company at Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd. -Zenith Pharmaceuticals Ltd acquires 71% shares through preferential issue route. -Board approves for the proposal of restructuring its Cram division by hiving off into two separate company under the provisions of the companies act. -Incorporates 'Strides Africa Ltd' at British Virgin Island with an authorised capital of US $ 200,000 as 100% wholly owned subsidiary. -Board decides to change the name of the company to 'Strides Arcolab (FA)' to reflect the change in the business focus and operations. 2003 -Nominates Mr Francis Pinto as the Director on the Board of the company. -Forges an exclusive co-operation alliance with the South Africa based drug manufacturer Aspen Pharmacare, mainly to share the product development expertise and quality systems. -Concludes the strategic development and manufacturing agreement with Sorm Co. Ltd for long term supply of Generics, OTC and Nutraceutical products. -Changes in the Management: Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr Krishna Kumar Menon as COO. -Board approves for the reorganization of subsidiaries of the company and for write off of dimunition in value of investments made in subsidiaries by the company. -Strides inks MoU with Ribbon SRL for Cephalosporin 2004 -Major Fire occurs in Private Custom Bonded warehouse in Mexico -Strides Arcolab Limited has entered into a memorandum of understanding with BITS, Pilani for an ``off campus collaborative programme''. As part of the partnership, Strides has launched a new initiative called STEP (Strides Training and Education Plan) intend to offer their employees an opportunity to acquire a MS in Pharma Operations & Management while on the job. 2005 - Enters into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd, to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets. -Strides Arcolab enters into an agreement for private placement issue - Strides Arcolab signs License Agreement with KV Pharma for exclusive marketing rights in the United States and Canada for 10 new generic drugs -Strides acquires sterile manufacturing facility in Poland 2007 - Strides Arcolab has got tentative permission from the United States Food and Drug Administration (USFDA) for Efavirenz tablets, an anti-HIV drug. Efavirenz, is the generic version of Bristol Myers Squibb's Sustiva, which helps in preventing the HIV virus from reproduction. - Strides Arcolab receives 2 more NDA approvals from US-FDA. 2008 - Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials. 2010 - Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been appointed as an Executive Director of the Company. 2011 -Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite -Strides announces First European Approval for Oncology Product -Strides Arcolab receives US FDA Nod to Commercialize First Liquid -StridesArcoL Update on acquisition of outstanding minority shareholding in Ascent Pharmahealth Limited -Strides Arcolab joins the Malaysian Bio-xcell Ecosystem 2012 -Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile -Strides Arcolab receives US FDA approval for Methotrexate Injection -Strides Arcolab Announces Health Canada Approval For Tobramycin Injection -Strides Arcolab acquires Sterile Formulations facility to expand core injectable biz -Strides collaborates with Gilead Sciences 2013 -Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet. - Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility. - Strides announces WHO pre-qualification for Artemether + Lumifantrine . -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology. -Strides Arcolab - Re-branding Biotech Business as ''Stelis''. -Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market. 2014 -- Medicines for Malaria Venture announces collaborations with Cipla and Strides. -Strides Arcolab makes strategic investment in Oncobiologics Inc., USA. - Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries. -Strides Arcolab receives US FDA approval for Buspirone Tablets. -Strides Arcolab receives US FDA approval for Calcitriol Softgel. -Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna. -Strides Arcolab to acquire Shasun Pharma in all stock deal. 2015 -Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc -Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc, -Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India "Virso" -Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350 -Strides Arcolab gets USFDA nod for HIV treatment drug -Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company. -Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia. -Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy -Strides Arcolab Ltd has changed from its present name "Strides Arcolab Limited" to "Strides Shasun Limited" 2016 -Strides Shasun updates on "Acquisition of seven brands from Johnson & Johnson". -Strides Shasun update on "Acquisition of CNS divisions of erstwhile Ranbaxy". -"Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia". -"Strides Shasun to acquire controlling stake in Universal Corporation, Kenya". -"Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet". - "Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore".

Registered Office

CHENNAI OFFICE: `Batra Centre', 3rd and 4th Floor, 28, Sardar Patel Road, Guindy,

044-43446700,22207500,,      044-22350278,

Registrar Details

Karvy Computershare Private Ltd.